{"id":"NCT02932306","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle- Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-03","primaryCompletion":"2017-02-22","completion":"2017-02-22","firstPosted":"2016-10-13","resultsPosted":"2020-01-03","lastUpdate":"2020-01-03"},"enrollment":820,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne"],"interventions":[{"type":"DRUG","name":"IDP-121 Lotion","otherNames":[]},{"type":"DRUG","name":"IDP-121 Vehicle Lotion","otherNames":[]}],"arms":[{"label":"IDP-121 Lotion","type":"EXPERIMENTAL"},{"label":"IDP-121 Vehicle Lotion","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score \\[EGSS\\] of 3 \\[moderate\\] or 4 \\[severe\\]).","primaryOutcome":{"measure":"Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12","timeFrame":"Baseline (Day 0), Week 12","effectByArm":[{"arm":"IDP-121 Lotion","deltaMin":-17.8,"sd":15.18},{"arm":"IDP-121 Vehicle Lotion","deltaMin":-10.6,"sd":16.07}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":39,"countries":["United States"]},"refs":{"pmids":["32886337"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":378},"commonTop":[]}}